Primary Hyperaldosteronism diagnostic
Diagnostic Testblood sample to obtain the aldosterone to renin ratio
NCT Number: NCT04115280
Atrial arrhythmia is the most frequent cardiac arrhythmia. It is a source of significant morbidity.
Hypertension is a major risk factor for atrial arrhythmias. Primary hyperaldosteronism (PA) is a common cause of secondary hypertension, associated with a high prevalence of arrhythmias with a specific, sometimes curative, treatment. The purpose of the study is to show that the prevalence of PA among hypertensive patients under 65 years old with atrial arrhythmia is high, justifying systematic screening.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Not applicable
CHU de Bordeaux, Bordeaux, France
Atrial arrhythmia is the most frequent cardiac arrhythmia, affecting one million patients in France. It is a source of significant morbidity, a major deterioration in the quality of life and considerable health expenditure.
Hypertension is a major and modifiable risk factor for atrial arrhythmias. Primary hyperaldosteronism is a common cause of secondary hypertension, associated with a high prevalence of arrhythmias, but also stroke, coronary artery disease, heart and kidney failure. This form has a specific treatment, sometimes curative.
The objective of this study is to show that the prevalence of primary hyperaldosteronism among patients under 65 with atrial arrhythmias is high, justifying systematic screening in this population.
The investigators will consecutively include 65-year-old hypertensive patients hospitalized in the department with atrialarrhythmia. They will benefit from an aldosterone to renin ratio assay under standardized conditions at 3 months.
Patients whose aldosterone (pmol/l) to renin (mUI/l) ratio is greater than 64 will benefit from saline infusion test if necessary and adrenal scan. Patients with a definite diagnosis who would prefer surgical treatment will benefit from adrenal venous catheterization.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
blood sample to obtain the aldosterone to renin ratio
Time frame: Data collected after the saline infusion test (6-month visit)
Prevalence of primary hyperaldosteronism among the enrolled population.
Centre Hospitalier de PAU
Other
Prevalence of Primary Aldosteronism Among Hypertensive Patients Younger Than 65 Years Old With Atrial Arythmia
Acronym: HAPAA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07700888
Adrenal Gland Diseases, Adrenocortical Hyperfunction
Beijing, 李泽文, China
View Trial DetailsNCT02756754
ACTH Syndrome, Ectopic, Adrenal Adenoma
Bordeaux, France
View Trial DetailsNCT04605549
Adrenal Gland Diseases, Adrenocortical Hyperfunction
Greenbrae, California, United States
View Trial DetailsNCT05757076
Adrenal Gland Diseases, Adrenocortical Hyperfunction
Cleveland, Ohio, United States
View Trial Details